We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA hit Eywa Pharma’s Cranbury, N.J., drug manufacturing facility with a three-observation Form 483, citing inadequate investigations of deviations and other quality lapses. Read More
The FDA issued skincare drug product developer Clinical Formula a five-observation Form 483 for lacking an effective quality control unit and other serious deficiencies observed during a November-December 2021 inspection of its Newport Beach, Calif., facility. Read More
The FDA hit Carlsbad, Calif.-based SAFC Carlsbad — a MilliporeSigma property — with a seven-observation Form 483 following a December 2021 inspection, citing inadequate handling of biohazardous materials and other quality lapses. Read More
The FDA issued a warning letter to a contract testing laboratory at Miami University in Oxford, Ohio, for significant deviations from current good manufacturing practice (cGMP), including falsified data. Read More
The FDA has issued a Form 483 to a drug manufacturer and repackager in Saint Paul, Minn., for multiple deficiencies observed during a Nov. 1-18, 2021 inspection of its facility, including several that were observed during previous inspections. Read More
Belcher Pharmaceuticals received a Form 483 from the FDA for several deficiencies observed during a Nov. 1- 15, 2021, inspection of its drug manufacturing facility in Largo, Fla. Read More
Baxter Pharmaceuticals Solutions’ contract manufacturing facility in Bloomington, Ind., has received a Form 483 for several deficiencies observed during an FDA inspection from Nov. 2 through Nov. 10, 2021. Read More
Drug compounding pharmacy Ideal Specialty Apothecary of Parsippany, N.J., has received a Form 483 detailing quality deficiencies observed during an FDA inspection from Sept. 13 through Nov. 18, 2021. Read More
The FDA has issued a Form 483 to Advanced Accelerator Applications, citing quality and laboratory control issues observed during an inspection of the company’s sterile drug manufacturing facility in Millburn, N.J. Read More
Agropharma Laboratories of Salinas, Puerto Rico, has received a three-observation Form 483 citing issues with laboratory controls, cleanliness of the facility and quality control. Read More
An FDA investigator observed that Belport, a drugmaker in Camarillo, Calif., doing business as Gingi-Pak, didn’t conduct microbiological testing of the water used to manufacture its drug products, among other quality lapses noted during a Nov. 8 to 12, 2021, inspection of its facility. Read More